id: NEW:sud_treatment_menu_diversity_to_sud_medication_treatment_rate_oud
name: SUD Treatment Menu Diversity â†’ SUD Medication Treatment Rate
from_node:
  node_id: NEW:sud_treatment_menu_diversity
  node_name: SUD Treatment Menu Diversity
to_node:
  node_id: sud_medication_treatment_rate_oud
  node_name: SUD Medication Treatment Rate
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Increased menu of approved pharmacological treatments expands clinician prescribing options'
- 'Step 2: Diverse treatment mechanisms (GABA modulation, glutamate antagonism, opioid antagonism, etc.)
  allow matching treatment to patient phenotype'
- 'Step 3: Personalized treatment approaches improve treatment retention and efficacy'
- 'Step 4: Higher medication treatment rates reduce alcohol consumption and related harms'
evidence:
  quality_rating: B
  n_studies: 22
  primary_citation: E. Burnette et al. 2022. "Novel Agents for the Pharmacological Treatment of Alcohol
    Use Disorder." https://doi.org/10.1007/s40265-021-01670-3
  supporting_citations:
  - Nalmefene studies (approved in Europe for AUD)
  - Topiramate efficacy studies for AUD treatment
  - Gabapentin studies showing promise for AUD treatment
  doi: 10.1007/s40265-021-01670-3
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: The paper emphasizes that expanding the menu of approved AUD pharmacotherapies advances precision
  medicine for this heterogeneous population. Multiple mechanisms of action (disulfiram-aversion, naltrexone-opioid
  antagonism, acamprosate-glutamate modulation, etc.) allow for personalized treatment matching.
spatial_variation:
  varies_by_geography: true
  variation_notes: Nalmefene is approved in Europe but not widely in other regions, demonstrating regulatory
    variation in treatment availability
moderators:
- name: Patient heterogeneity
  direction: strengthens
  strength: strong
  description: The heterogeneous nature of AUD means diverse treatment options are essential for effective
    population-level treatment
- name: Precision medicine advancement
  direction: strengthens
  strength: moderate
  description: Advancement of precision medicine and personalized treatment approaches enhances the utility
    of diverse pharmacotherapies
structural_competency:
  equity_implications: This represents a structural healthcare system intervention - expanding approved
    treatment options is a policy and regulatory matter rather than individual behavior change. The emphasis
    on heterogeneity acknowledges that one-size-fits-all approaches fail diverse patient populations.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.239172'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
